Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2013—Hamilton Robotics has launched a next-generation, liquid-handling platform that offers contact-free pipetting over a wide volume range. The Hamilton Vantage is space efficient, affordable, and can be remotely monitored by mobile devices. Its expandable design makes it a powerful instrument for labs performing simple or complex applications.
December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.
December 2013—New Purair 5 ductless fume hoods from Air Science USA feature a high level of operator protection where routine work is being carried out. The units exceed OSHA, ANSI, and all relevant international standards, operate at low noise levels, and recirculate rather than exhaust expensive conditioned or heated air into the atmosphere.
December 2013—Sequenom has announced a certified service provider program for the technical certification of selected laboratories offering research services using the Sequenom research-use-only MassArray system. Certifications cover the major research applications of the MassArray system, including iPlex genotyping, OncoCarta somatic mutation profiling, ADME PGx, and EpiTyper DNA methylation analysis.
December 2013—The Clinical and Laboratory Standards Institute has released the latest version of a document addressing the design of measurement procedure comparisons using patient samples and subsequent data-analysis techniques for determining the bias between two in vitro diagnostic measurement procedures.
December 2013—Mettler Toledo has released a series of free 30- to 45-minute video tutorials that provide insights into the topics of pipetting, weighing, pH determination, and thermal analysis.
December 2013—Randox’s two new controls, Acusera Liquid Assayed Chemistry Premium and Premium Plus, are designed to drastically cut the number of individual quality controls a laboratory needs to run in routine medical testing while providing clinically significant values for a wide range of analyzers at key decision points.
December 2013—Torrey Pines Scientific’s new EchoTherm stackable, programmable chilling incubators have a 27-L capacity and are Peltier based for heating and chilling. The incubators have no compressors or CFCs and are vibration free, making them ideal for protein crystallizations. Additional applications include incubating marine samples below room temperature, enzyme reactions and deactivations, hybridizations, ligations, and storing oocytes.
December 2013—Definiens AG, a health care company that advances personalized medicine through image-analysis and digital pathology solutions, and Advanced Cell Diagnostics (ACD), a provider of products and services for molecular pathology, announced the commercial launch of RNAscope SpotStudio, a custom-designed image-analysis software application for ACD’s RNAscope assays to detect and quantify RNA biomarkers.
December 2013—Skuldtech, a genomic biomarker company, has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer disease that has received funding of EUR 8.6 million in total. The program is scheduled to last four years, with the first results expected in 2018.
